Shree Ganesh Remedies Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: SGRL BSE: 540737

₹687.15

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #92 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Shree Ganesh Remedies Limited (this stock)	882	57.2	10.9%	—	—	54	6	58

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹899 Cr

EV / EBITDA

26.2x

EV / Sales

9.09x

Market cap / Sales

8.91x

Earnings yield

1.75%

Quarterly Financials

Download CSV

Standalone Consolidated

↓ Negative

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 15 Cr, down 39.6% YoY.

↓ Negative

Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 1 Cr, down 67.5% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	14	2	1	₹0.8700
March 31, 2026	33	9	6	₹4.8800
Dec. 31, 2025	21	4	3	₹2.4100
Sept. 30, 2025	30	7	5	₹3.8600
June 30, 2025	25	5	3	₹2.6900
March 31, 2025	24	9	7	₹5.1300
Dec. 31, 2024	27	8	5	₹4.2300
Sept. 30, 2024	32	9	6	₹4.9800
June 30, 2024	25	6	5	₹3.6200
March 31, 2024	37	16	13	₹10.0100
Dec. 31, 2023	28	7	5	₹3.8370
Sept. 30, 2023	33	9	7	₹5.3210
June 30, 2023	27	6	5	₹3.8600

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	15	34	22	31	25	27	28	33	25	39	29	34	27
Operating revenue	14	33	21	30	25	24	27	32	25	37	28	33	27
Other income	1	1	1	1	1	2	1	0	1	1	1	1	1
Operating expenses	11	22	14	21	17	15	17	21	17	20	20	24	20
Operating profit	3	11	7	10	7	10	10	11	8	17	8	9	7
Operating profit margin	23.3%	34.3%	31.9%	31.7%	29.6%	40.4%	36.6%	35.0%	32.8%	45.4%	29.3%	27.6%	25.3%
Depreciation	2	3	3	3	2	2	3	2	2	2	2	1	1
Interest	0	1	1	1	1	1	0	0	0	0	0	0	0
Exceptional items, gain / (loss)	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit before tax	2	9	4	7	5	9	8	9	6	16	7	9	6
Tax	0	2	1	2	1	2	2	2	2	4	3	2	2
Net profit	1	6	3	5	3	7	5	6	5	13	5	7	5
EPS	0.87	4.88	2.41	3.86	2.69	5.13	4.23	4.98	3.62	10.01	3.84	5.32	3.86
Net profit (TTM)	15	18	18	20	22	23	29	28	29	29	22	22	19
EPS (TTM)	12.02	13.84	14.09	15.91	17.03	17.96	22.84	22.45	22.79	23.03	17.80	17.58	15.54

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22
Total income (before exceptional items)	6.3%	—	112^†	112^†	129^†	93^†	75^†
Operating revenue	6.6%	—	109^†	109^†	125^†	90^†	71^†
Other income	—	—	3^†	4^†	4^†	3^†	4^†
Operating expenses	—	—	74^†	69^†	84^†	67^†	53^†
Operating profit	14.2%	—	35^†	39^†	41^†	23^†	18^†
Operating profit margin	—	—	32.0%^†	36.1%^†	32.8%^†	26.0%^†	25.1%^†
Depreciation	—	—	10^†	10^†	6^†	4^†	3^†
Interest	—	—	4^†	2^†	0^†	0^†	0^†
Exceptional items, gain / (loss)	—	—	0^†	0^†	0^†	0^†	0^†
Profit before tax	2.1%	—	24^†	31^†	39^†	23^†	18^†
Tax	—	—	6^†	8^†	10^†	6^†	5^†
Net profit	1.5%	—	18^†	23^†	29^†	17^†	13^†
EPS	-0.5%	—	13.84^†	17.96^†	23.03^†	14.07^†	12.06^†

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22
Operating margin	32.0%^†	36.1%^†	32.8%^†	26.0%^†	25.1%^†
EBIT margin	25.2%^†	30.7%^†	31.0%^†	25.5%^†	25.5%^†
PBT margin	22.0%^†	28.8%^†	30.9%^†	25.0%^†	25.3%^†
Net margin	16.3%^†	21.3%^†	22.9%^†	18.9%^†	18.8%^†
Interest coverage	7.74x^†	16.07x^†	212.00x^†	56.96x^†	124.41x^†
Dividend payout	—	—	—	—	—
Earnings retention	—	—	—	—	—
Current ratio	3.96x	4.79x	—	—	—
Quick ratio	2.85x	3.43x	—	—	—
Debt to equity	0.19x	0.26x	—	—	—
Return on equity	10.9%^†	15.9%^†	—	—	—
Return on assets	8.6%^†	12.0%^†	—	—	—
Return on capital employed	14.8%^†	19.0%^†	—	—	—
Asset turnover	0.53x^†	0.57x^†	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	24	-10	-12	17	7
March 31, 2025	31	-36	-1	23	7

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	208	163	150	9	21	86	22	13	68	24
March 31, 2025	192	145	132	9	29	78	16	10	58	22

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.